Teva Pharm (TEVA) Tops Q2 EPS by 1c
More News related to TEVA
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
- Morning Movers 12/01: PEIX, SYMX, GSIT, HDY, GES, BPFH Higher; LTON, OVTI, PLX Lower
- Teva Pharma (TEVA) Submits BLA to U.S. FDA for XM02
- Teva Pharma (TEVA) and Codexis Sign Second Agreement This Year
More News related to Earnings
- Highlights From SWHC Q2 Conference Call: First Qtr Reflected Results From Two Segments Under S&W Umbrella; Guides Below for Q3
- NASB Financial (NASB) Posts Q4 EPS of $0.77, Tops Views
- Highlights From Take-Two Interactive Softwares' (TTWO) Forecast Teleconference
- Saks (SKS) Restates Q3 EPS to $0.04, Up from $0.01
- Big Lots (BIG) Delivers With Strong Q3 Results and Guidance
Teva Pharm (Nasdaq: TEVA) reports Q2 earnings of $0.65 per share, above the consensus of $0.64. Revenues came in at $2.82 billion, versus the consensus of $2.68 billion.
Related Categories
EarningsStocks Mentioned
+0.44Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
